HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A systematic review and meta-analysis of the safety and efficacy of remifentanil and dexmedetomidine for awake fiberoptic endoscope intubation.

AbstractBACKGROUND:
Awake fiberoptic endoscope intubation (AFOI) is the primary strategy for managing anticipated difficult airways. Adequate sedation, most commonly being achieved with remifentanil and dexmedetomidine, is integral to this procedure. This meta-analysis aimed to compare the safety and efficacy of these 2 sedatives.
METHODS:
We conducted electronic searches in Embase, Web of Science, PubMed, Google Scholar, Medline, Springer, and Web of Science with no language restrictions. Studies comparing safety and efficacy between the sole use of remifentanil and dexmedetomidine among patients who underwent AFOI were included. Eight randomized controlled trials, comprising 412 patients, met the inclusion criteria. The primary outcomes were first attempt intubation success rate and incidence of hypoxia. The secondary outcomes were the Ramsay Sedation Scale score at intubation, memory recall of endoscopy, and unstable hemodynamic parameters during intubation.
RESULTS:
Dexmedetomidine significantly reduced the incidence of hypoxemia during AFOI (risk ratio: 2.47; 95% confidence [CI]: 1.32-4.64]) compared with remifentanil; however, the first intubation success rates were equivalent (risk ratio: 1.12; 95% CI: 0.87-1.46]. No significant differences between the 2 sedatives were found for the Ramsay Sedation Scale score at intubation (mean difference: -0.14; 95% CI: -0.66-0.38) or unstable hemodynamic parameters during intubation (risk ratio: 0.83; 95% CI: 0.59-1.17). Dexmedetomidine reduced memory recall of endoscopy (risk ratio: 1.39; 95% CI: 1.13-1.72).
CONCLUSIONS:
While both remifentanil and dexmedetomidine are effective for AFOI and well-tolerated, dexmedetomidine may be more effective in reducing the incidence of hypoxemia and memory recall of endoscopy.
PROSPERP REGISTRATION NUMBER:
CRD42020169612.
AuthorsZhi-Hang Tang, Qi Chen, Xia Wang, Nan Su, Zhengyuan Xia, Yong Wang, Wu-Hua Ma
JournalMedicine (Medicine (Baltimore)) Vol. 100 Issue 14 Pg. e25324 (Apr 09 2021) ISSN: 1536-5964 [Electronic] United States
PMID33832107 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)
CopyrightCopyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Chemical References
  • Hypnotics and Sedatives
  • Dexmedetomidine
  • Remifentanil
Topics
  • Conscious Sedation (methods)
  • Dexmedetomidine (administration & dosage, adverse effects, therapeutic use)
  • Endoscopy (instrumentation, methods)
  • Fiber Optic Technology
  • Hemodynamics
  • Humans
  • Hypnotics and Sedatives (administration & dosage, adverse effects, therapeutic use)
  • Hypoxia (epidemiology)
  • Intubation, Intratracheal (methods)
  • Randomized Controlled Trials as Topic
  • Remifentanil (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: